论文部分内容阅读
目的:α-干扰素联合吉西他滨(GEM)术后即刻膀胱灌注与常规灌注预防膀胱癌复发的对比研究。方法:按照灌注时间的不同,将53例表浅性膀胱癌患者经尿道膀胱肿瘤电切术(TURB-t)后分为两组:观察组(27例)于术后24h内即刻开始α-干扰素联合GEM灌注,对照组(26例)于术后1周开始α-干扰素联合GEM灌注。评价患者随访期内的复发率及药物毒副作用。结果:随访2年,观察组复发率7.4%(2/27),对照组复发率19.2%(5/26),两组对比差异有统计学意义(P<0.05)。膀胱灌注过程当中6例发生血尿、膀胱炎、尿道刺激症等不良反应,两组比较无统计学差异(P>0.05)。结论:α-干扰素联合GEM术后即刻膀胱灌注可有效降低表浅性膀胱癌患者术后的复发率,且毒副作用小。
OBJECTIVE: To compare the efficacy of intravesical instillation and conventional perfusion of interferon alpha combined with gemcitabine (GEM) in the prevention of bladder cancer recurrence. Methods: According to the different perfusion time, 53 cases of superficial bladder cancer were divided into two groups by transurethral resection of bladder tumor (TURB-t): The observation group (27 cases) started α- Interferon combined with GEM perfusion and control group (n = 26) started α-interferon combined with GEM perfusion at 1 week after operation. Evaluation of patients during the follow-up of the recurrence rate and drug side effects. Results: The follow-up of 2 years showed that the recurrence rate was 7.4% (2/27) in the observation group and 19.2% (5/26) in the control group. There was significant difference between the two groups (P <0.05). Six cases of bladder perfusion occurred hematuria, cystitis, urethral irritation and other adverse reactions, no significant difference between the two groups (P> 0.05). CONCLUSION: Intravesical instillation of IFN-α combined with GEM can effectively reduce the postoperative recurrence rate of patients with superficial bladder cancer with less side effects.